Patents by Inventor Steven Mark Wenglowsky

Steven Mark Wenglowsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170029409
    Abstract: Compounds and compositions useful for treating disorders related to Kit are described herein.
    Type: Application
    Filed: October 17, 2016
    Publication date: February 2, 2017
    Inventors: Lucian V. DiPietro, Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu, Steven Mark Wenglowsky, Douglas Wilson, Yulian Zhang
  • Patent number: 9499522
    Abstract: Compounds and compositions useful for treating disorders related to Kit are described herein.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 22, 2016
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Lucian V. DiPietro, Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu, Steven Mark Wenglowsky, Douglas Wilson, Yulian Zhang
  • Patent number: 9133187
    Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z3, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: September 15, 2015
    Assignees: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: James F. Blake, Huifen Chen, Mark Joseph Chicarelli, Jason Demeese, Rustam Garrey, John J. Gaudino, Robert J. Kaus, Gabrielle R. Kolakowski, Allison L. Marlow, Peter J. Mohr, Li Ren, Jacob Schwarz, Christopher S. Siedem, Allen A. Thomas, Eli Wallace, Steven Mark Wenglowsky, Steven Boyd
  • Publication number: 20140296206
    Abstract: Compounds and compositions useful for treating disorders related to Kit are described herein.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Lucian V. DiPietro, Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu, Steven Mark Wenglowsky, Douglas Wilson, Yulian Zhang
  • Publication number: 20130338140
    Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: February 28, 2012
    Publication date: December 19, 2013
    Applicants: Genetech, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Huifen Chen, Mark Joseph Chcarelli, Jason Demeese, Rustam Garrey, John J. Gaudino, Robert J. Kaus, Gabrielle R. Kolakowski, Allison L. Marlow, Peter J. Mohr, Li Ren, Jacob Schwartz, Christopher S. Siedem, Allen A. Thomas, Eli Wallace, Steven Mark Wenglowsky
  • Patent number: 8394795
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: March 12, 2013
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: Kateri A. Ahrendt, Alexandre J. Buckmelter, Jason De Meese, Jonas Grina, Joshua D. Hansen, Ellen R. Laird, Paul Lunghofer, David Moreno, Brad Newhouse, Li Ren, Jeongbeob Seo, Hongqi Tian, Steven Mark Wenglowsky, Bainian Feng, Janet Gunzner, Kim Malesky, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Wendy B. Young
  • Publication number: 20130018033
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: January 17, 2013
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Wendy Lee, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Guiling Zhao, Alexandre J. Buckmelter, Jonas Grina, Joshua D. Hansen, Ellen Laird, David Moreno, Li Ren, Steven Mark Wenglowsky
  • Publication number: 20120157453
    Abstract: Compounds of Formula II are useful for inhibition of Raf kinases. Methods of using compounds of Formula II and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: June 21, 2012
    Applicants: GENENTECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Simon Mathieu, Joachim Rudolph, Zhaoyang Wen, Steven Mark Wenglowsky
  • Publication number: 20120157439
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: June 21, 2012
    Applicants: GENENTECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Ignacio Aliagas, Stefan Gradl, Janet Gunzner, Simon Mathieu, Rebecca Pulk, Joachim Rudolph, Zhaoyang Wen, Jonas Grina, Joshua D. Hansen, Ellen Laird, David Moreno, Li Ren, Steven Mark Wenglowsky
  • Publication number: 20120157452
    Abstract: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 27, 2010
    Publication date: June 21, 2012
    Applicants: GENENTECH, INC., ARRAY BIOPHARMA INC.
    Inventors: Stefan Gradl, Ellen Laird, David Moreno, Li Ren, Steven Mark Wenglowsky
  • Publication number: 20100063066
    Abstract: Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 31, 2007
    Publication date: March 11, 2010
    Applicant: Array Biopharma, Inc.
    Inventors: Alexandre J. Buckmelter, Joseph P. Lyssikatos, Greg Miknia, Li Ren, Steven Mark Wenglowsky, Bryson Rast
  • Publication number: 20090203585
    Abstract: The present invention relates to phenylurea derivatives of capreomycin I, IIB, IIA, or IB, and metabolites and pharmaceutically acceptable salts and solvates thereof. The compounds of the present invention are useful as antibacterial agents for treating bacterial infections and for treating disorders caused by bacterial infections. The present invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial infections by administering such compounds. The present invention also relates to methods of preparing such compounds.
    Type: Application
    Filed: March 13, 2007
    Publication date: August 13, 2009
    Inventors: Joseph P. Lyssikatos, Steven Mark Wenglowsky, D. David Hennings, Daniel John Watson
  • Patent number: 7294616
    Abstract: The present subject matter relates to phenylurea capreomycin derivatives, and to metabolites and pharmaceutically acceptable salts and solvates thereof. The compounds of the present subject matter are useful as antibacterial agents for treating bacterial infections and for treating disorders caused by bacterial infections. The present subject matter also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial infections by administering such compounds. The present subject matter also relates to methods of preparing such compounds.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: November 13, 2007
    Assignee: Array BioPharma, Inc.
    Inventors: Joseph P. Lyssikatos, Steven Mark Wenglowsky